BioSpace News Archive

Arcutis Biotherapeutics, Inc. announced results of a nationwide survey of adults with seborrheic dermatitis and the healthcare providers who treat them that highlights the long path to diagnosis and the general lack of awareness and education about the disease.

CinCor Pharma, Inc. (NASDAQ: CINC) today announced the publication of Phase 1 clinical data for baxdrostat, a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase, in the journal Hypertension Research.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced a research agreement with a Top 10 Global Healthcare company (“Healthcare Company”) (based on 2021 revenues).

SK bioscience announced that Dr. Harry Kleanthous, formerly Senior Program Officer in Global Health at the Bill & Melinda Gates Foundation, has joined the Company as Executive Vice President of Vaccine R&D Strategy and External Innovation.

DNAnexus, Inc., the leader in biomedical informatics and data management, announced the appointment of Jeff Margolis, a seasoned healthcare information technology executive and current Senior Advisor for Blackstone, to its Board of Directors.

Akebia Therapeutics, Inc. today announced that it will present data at the American Society of Nephrology Kidney Week 2022 ( ASN Kidney Week 2022 ), which will take place in Orlando, November 3-6, 2022.

Onshoring pharmaceutical manufacturing has become a priority in the United States and is even backed by a $2 billion federal investment.

Genesys Spine announced today the first two patients have been enrolled in the prospective SIros™ Lateral Sacroiliac Fusion Study.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VPO-227 for the treatment of cholera.

ANGLE plc, a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 25,000 new ordinary shares of £0.10 each in the Company.